JPWO2018199224A1 - 抗アレルギー剤 - Google Patents

抗アレルギー剤 Download PDF

Info

Publication number
JPWO2018199224A1
JPWO2018199224A1 JP2019514614A JP2019514614A JPWO2018199224A1 JP WO2018199224 A1 JPWO2018199224 A1 JP WO2018199224A1 JP 2019514614 A JP2019514614 A JP 2019514614A JP 2019514614 A JP2019514614 A JP 2019514614A JP WO2018199224 A1 JPWO2018199224 A1 JP WO2018199224A1
Authority
JP
Japan
Prior art keywords
allergic
agent
quinolone antibacterial
antiallergic
antiallergic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514614A
Other languages
English (en)
Japanese (ja)
Inventor
木村　隆仁
隆仁 木村
繁人 藤下
繁人 藤下
塩田　聡
聡 塩田
健治 麻生
健治 麻生
一志 老田
一志 老田
威佐男 堀内
威佐男 堀内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teika Pharamaceutical Co Ltd
Original Assignee
Teika Pharamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teika Pharamaceutical Co Ltd filed Critical Teika Pharamaceutical Co Ltd
Publication of JPWO2018199224A1 publication Critical patent/JPWO2018199224A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019514614A 2017-04-27 2018-04-26 抗アレルギー剤 Pending JPWO2018199224A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017088324 2017-04-27
JP2017088324 2017-04-27
PCT/JP2018/016963 WO2018199224A1 (ja) 2017-04-27 2018-04-26 抗アレルギー剤

Publications (1)

Publication Number Publication Date
JPWO2018199224A1 true JPWO2018199224A1 (ja) 2020-03-12

Family

ID=63920378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514614A Pending JPWO2018199224A1 (ja) 2017-04-27 2018-04-26 抗アレルギー剤

Country Status (3)

Country Link
JP (1) JPWO2018199224A1 (zh)
TW (1) TWI755524B (zh)
WO (1) WO2018199224A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09255659A (ja) * 1996-01-17 1997-09-30 Dainippon Ink & Chem Inc キノリノン誘導体及びそれを有効成分とする抗アレルギー剤
JP2009161454A (ja) * 2007-12-28 2009-07-23 Lion Corp 眼科用組成物
JP6474913B2 (ja) * 2015-10-29 2019-02-27 テイカ製薬株式会社 外用剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09255659A (ja) * 1996-01-17 1997-09-30 Dainippon Ink & Chem Inc キノリノン誘導体及びそれを有効成分とする抗アレルギー剤
JP2009161454A (ja) * 2007-12-28 2009-07-23 Lion Corp 眼科用組成物
JP6474913B2 (ja) * 2015-10-29 2019-02-27 テイカ製薬株式会社 外用剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.ARANDA ET AL.: "In vitro evaluation of IgE-mediatied hypersensitivity reactions to quinolones", ALLERGY, vol. 66, JPN6018024324, 2011, pages 247 - 254, XP055527863, ISSN: 0004766715, DOI: 10.1111/j.1398-9995.2010.02460.x *
BIELORY,MD LEONARD: "Ocular Allergy Overview", IMMNOLOGY AND ALLERGY CLINICS OF NORTH AMEICA, vol. 28, JPN6018024322, 2008, pages 1 - 23, ISSN: 0004766716 *
CLAERHOUT, I ET AL.: "Corneal deposits after the topical use of ofloxacin in two children with vernal keratoconjunctivitis", BR. J. OPHTHALMOL., vol. 87, JPN6018024308, 2003, pages 646, XP055527851, ISSN: 0004766711, DOI: 10.1136/bjo.87.5.646 *
YAMASHITA,HIROKO ET AL.: "Contact dermatitis from amlexanox eyedrops", CONTACT DERMATITIS, vol. 25, JPN6018024310, 1991, pages 255 - 256, ISSN: 0004766712 *
塩田聡 他: "ガチフロキサシンはケトチフェンの抗アレルギー作用を増強する", 第３７回日本眼薬理学会 プログラム抄録集, JPN6018024327, 2 September 2017 (2017-09-02), pages 54, ISSN: 0004766717 *
海老原伸行: "アトピー性眼瞼炎", 眼科, vol. 46, no. 5, JPN6018024320, 5 May 2004 (2004-05-05), pages 681 - 687, ISSN: 0004766714 *
雑賀寿和: "アトピー性角結膜炎の薬物療法", PHARMA MEDICA, vol. 10, no. 6, JPN6018024317, 10 June 1992 (1992-06-10), pages 153 - 155, ISSN: 0004766713 *

Also Published As

Publication number Publication date
WO2018199224A1 (ja) 2018-11-01
TW201842934A (zh) 2018-12-16
TWI755524B (zh) 2022-02-21

Similar Documents

Publication Publication Date Title
CN111356451A (zh) 炎性病症的治疗
TWI578990B (zh) 眼睛過敏之治療
JP7082162B2 (ja) マイボーム機能不全の治療剤
ES2370751T3 (es) Agente profiláctico o terapéutico para la degeneración macular asociada a la edad.
TW201737943A (zh) 使用fasn抑制劑之方法
JP7248836B2 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
TW201442710A (zh) 用以避免或治療乾眼症之含瑞巴派特或其前藥之口服藥物組成
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
JP6351629B2 (ja) 点眼用組成物
CN104173286B (zh) 氮卓斯汀组合物和用途
JPWO2018199224A1 (ja) 抗アレルギー剤
JP6509244B2 (ja) 水晶体硬化抑制剤
TWI713618B (zh) 外用劑
CA3014071A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
WO2016196989A1 (en) Topical composition
KR101227230B1 (ko) 플루오로퀴놀론을 사용하여 안내염을 조절하기 위한 조성물 및 방법
JP6231783B2 (ja) 完全フロイントアジュバント投与による眼瞼状態の変化方法
CA3037116A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
JP2015229671A (ja) 網膜色素上皮細胞保護剤
US20110166126A1 (en) Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones
TW202237075A (zh) 抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法
WO2004069822A1 (ja) ステロイド副作用抑制組成物
JP2005187458A (ja) シロミラストまたはその塩を有効成分とする掻痒治療剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025